GleamWall
中文EN

ABEO ABEONA THERAPEUTICS INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 318306 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-175.9%
TTM EPS YoY-189.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin65.1%
Operating margin-186.1%
Net margin-160.3%
FCF margin-170.1%
EBITDA margin-178.5%

Returns

ROE-42.1%
ROA-31.0%
ROIC (approx.)-59.9%
Asset turnover0.19x

Leverage & solvency

Liabilities / assets26.8%
Debt / equity0.19x
Current ratio5.69x
Interest coverage-24.47x

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio0.5%
Payout ratio—
Capex / revenue7.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$5.82M—
Cost of revenue$1.53M—
Gross profit$4.29M—
R&D expense$26.81M$34.36M
SG&A expense$65.03M$29.85M
Operating income-$89.45M-$64.21M
Interest expense$3.74M$4.21M
Pretax income$71.28M-$63.73M
Income tax$100,000—
Net income$71.18M-$63.73M
EBITDA-$86.90M-$62.21M
EPS (basic)1.34-1.55
EPS (diluted)1.01-1.55
Weighted avg. shares (diluted)66.14M41.05M
Balance sheet
Cash & equivalents$78.44M$23.36M
Short-term investments$112.97M$74.36M
Receivables$6.15M—
Inventory$5.49M—
Current assets$204.91M$100.85M
PP&E, net$9.92M$4.43M
Total assets$219.57M$108.93M
Current liabilities$29.57M$16.59M
Short-term debt$12.22M$5.93M
Long-term debt$7.81M$13.04M
Total debt$20.04M$18.96M
Total liabilities$60.35M$64.90M
Shareholders' equity$159.22M$44.03M
Net debt-$58.40M-$4.39M
Shares outstanding55.04M45.64M
Cash flow statement
Operating cash flow-$76.33M-$56.02M
Capital expenditure$7.97M$2.45M
Free cash flow-$84.30M-$58.46M
Investing cash flow$105.03M-$39.24M
Financing cash flow$26.04M$104.14M
Depreciation & amortization$2.55M$2.00M
Stock-based compensation$10.78M$6.63M

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.